Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma.
We have recently described the enzymatic subunit of telomerase (hTERT) as an important prognostic marker for paediatric ependymoma. Because of the lack of good, representative pre-clinical models for ependymoma, we took advantage of our large cohort of ependymoma patients, some with multiple recurrences, to investigate telomere biology in these tumours. Our cohort consisted of 133 ependymomas from 83 paediatric patients and included 31 patients with recurrences. Clinical outcome was measured as overall survival, progression-free survival and response to therapy. In all 133 tumours, hTERT expression correlated with proliferative markers, including MIB-1 index (P<0.0001) and mitotic index (P=0.005), as well as overall tumour grade (P=0.001), but not with other markers of anaplasia. There was no correlation between telomere length and hTERT expression or survival. Surprisingly, prior radiation or chemotherapy neither induced sustained DNA damage nor affected telomere maintenance in recurrent tumours. There was an inverse correlation between hTERT expression and telomere dysfunction as measured by gamma H2AX expression (P=0.016). Combining gamma H2AX and hTERT expressions could segregate tumours into three different survival groups (log rank, P<0.0001) such that those patients whose tumours expressed hTERT and showed no evidence of DNA damage had the worst outcome. This study emphasises the importance of telomere biology as a prognostic tool and telomerase inhibition as a therapeutic target for paediatric ependymoma. Furthermore, we have demonstrated that analysing tumours as they progress in vivo is a viable approach to studying tumour biology in humans.
Tabori
U
U
Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Wong
V
V
Ma
J
J
Shago
M
M
Alon
N
N
Rutka
J
J
Bouffet
E
E
Bartels
U
U
Malkin
D
D
Hawkins
C
C
D016543:Central Nervous System Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D002648:Child; D015331:Cohort Studies; D004806:Ependymoma / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis; D012008:Recurrence; D016615:Telomere
Neoplasia. 2006 Feb;8(2):136-42
16611406
Mod Pathol. 2008 Feb;21(2):165-77
18084249
Trends Biotechnol. 2001 Mar;19(3):114-20
11179805
Med Pediatr Oncol. 2001 Feb;36(2):268-73
11452934
Cell. 2000 Jan 7;100(1):57-70
10647931
J Clin Oncol. 2006 Apr 1;24(10):1522-8
16575002
Lancet. 2003 Mar 8;361(9360):836-8
12642053
Pediatr Blood Cancer. 2006 May 1;46(5):604-13
16086408
Acta Neuropathol. 2005 Jan;109(1):69-92
15647946
Histochem Cell Biol. 2004 May;121(5):391-7
15138842
J Neurooncol. 1996 Feb;27(2):111-5
8699232
Lab Invest. 2001 Oct;81(10):1331-8
11598146
Curr Biol. 2003 Sep 2;13(17):1549-56
12956959
Hum Pathol. 1998 Jun;29(6):599-603
9635680
Cancer Cell. 2006 May;9(5):391-403
16697959
Clin Cancer Res. 2004 Nov 15;10(22):7613-20
15569993
Childs Nerv Syst. 2002 Apr;18(3-4):112-7
11981616
Curr Neurol Neurosci Rep. 2005 Mar;5(2):107-9
15743547
Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31
9589080
Cell Cycle. 2007 Mar 1;6(5):546-9
17312399
Cancer Res. 2007 Feb 1;67(3):1121-9
17283146
Nature. 2003 Nov 13;426(6963):194-8
14608368